医疗特长：1996年大学本科毕业，曾于美国霍普金斯大学医学院进行博士后研究工作。一直从事消化内科临床工作，特别擅长功能性胃肠病（包括肠易激综合征、功能性消化不良、慢性便秘）及胃食管反流病的临床诊治；对急、慢性胰腺炎等各种胰腺疾病及肝脏疾病（包括病毒性肝炎、肝硬化、自身免疫性肝病及遗传性肝病）的处理积累了丰富的临床经验；擅长攻克各种疑难杂症。

社会兼职：

• • 中华医学会消化分会胃肠功能性疾病协作组副组长
  • 中华便秘医学会学术部委员会副会长
  • 广东省健康管理学会胰腺疾病专业委员会副主委
  • 中华消化心身联盟广东省委员会首届常务理事

发表通信和第一作者SCI论著：

1. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Alimentary Pharmacology & Therapeutics 2004; 19:1217-24.（第一）
2. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: A population-based study in South China. Scandinavian Journal of Gastroenterology 2005; 40:759-67.（共一）
3. Stratification and symptom characteristics of non-erosive reflux disease based on acid and duodenogastroesophageal reflux. Journal of Gastroenterology and Hepatology 2008; 23:290-5. （第一）
4. Prevalence and risk factors of Barrett's esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms. Journal of Digestive Diseases 2010; 11:83-7. （第一）
5. Cognitive-behavioral therapy for irritable bowel syndrome: A meta-analysis. Journal of Psychosomatic Research 2014; 77:1-12.（通信）
6. Control of Foxo1 Gene Expression by Co-activator P300. Journal of Biological Chemistry 2014; 289:4326-33.（共一）
7. The spectra, symptom profiles and overlap of Rome III functional gastrointestinal disorders in a tertiary center in South China. Journal of Digestive Diseases 2014; 15:538-44.（第一）
8. Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: A prospective randomized study. Digestive and Liver Disease 2015; 47:280-4.（第一）
9. Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome. Digestive and Liver Disease 2016; 48:880-7.（通信）
10. Natural history of adult-onset Menetrier's disease: Report of a case with 9-year follow-up. Experimental and Therapeutic Medicine 2016; 11:2462-6.（通信）
11. Rome foundation Asian working team report: Real world treatment experience of Asian patients with functional bowel disorders. Journal of Gastroenterology and Hepatology 2017; 32:1450-6.（第一）
12. Prevalence of lactose intolerance in patients with diarrhea-predominant irritable bowel syndrome: data from a tertiary center in southern China. Journal of Health Population and Nutrition 2017; 36.（第一）
13. Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology 2017; 32:28-38.（通信）
14. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome. Frontiers in Microbiology 2018; 9. （通信）
15. Peroxisome Elevation Induces Stem Cell Differentiation and Intestinal Epithelial Repair. Developmental Cell 2020; 53: 169-184.e11.（共一）
16. The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome. Bmc Gastroenterology 2020; 20.（通信）
17. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. Bmc Gastroenterology 2020; 20.（通信）
18. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. Bmc Gastroenterology 2021; 21.（通信）
19. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome. Frontiers in Cellular and Infection Microbiology 2021; 11.（通信）
20. Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation. Journal of Health Population and Nutrition 2022; 41.（通信）
21. Gastrointestinal bleeding caused by metastatic testicular choriocarcinoma: a case report and literature review. World Journal of Surgical Oncology 2022; 20.（通信）
22. Intestinal crosstalk between bile acids and microbiota in irritable bowel syndrome. Journal of Gastroenterology and Hepatology 2023; 38:1072-82.（通信）
23. Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites. Nutrients 2023; 15.（通信）
24. Efficacy and safety of Bifidobacterium quadruple viable tablets combined with mosapride citrate in the treatment of constipation in China: a systematic review and meta-analysis. Bmc Gastroenterology 2023; 23.（通信）
25. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients 2023; 15.（通信）
26. Multiomics Analysis Reveals Gut Virome-Bacteria-Metabolite Interactions and Their Associations with Symptoms in Patients with IBS-D. Viruses 2024 Jun 29; 16(7): 1054.（通信）
27. Diagnostic accuracy of a simplified tool for irritable bowel syndrome with predominant constipation in Chinese patients: A multicenter, prospective, observational study. Chin Med J (Engl). 2024 Oct 20; 137(20): 2509-11.（通信）
28. Bifidobacterium Lactobacillus Triple Viable Alleviates Slow Transit Constipation by Regulating Gut Microbiota and Metabolism. J Gastroenterol Hepatol. 2025 Jun; 40(6): 1561-1573.（通信）
29. Werner syndrome exonuclease promotes gut regeneration and causes age-associated gut hyperplasia in Drosophila. PLoS Biol. 2025 Apr 22;23(4): e3003121.（共一）

其他工作成绩：

1）获抗击非典三等功及广州抗击非典先进个人；

2）《胃食管反流病的系列研究》获2013 年广州市科学技术奖励科技进步类 一等奖；

3）主持国家自然科学基金、广东省科技计划、广东省自然科学基金、中山大学青年教师基金及广东省医学科研基金等各类科研项目；

4）作为核心专家，执笔书写2013年《中国慢性便秘诊治指南》、2015年《中国肠易激综合征专家共识意见》）、《2019年中国慢性便秘共识意见》、《2020年中国肠易激综合征专家共识意见》、2024年《双歧杆菌四联活菌片在消化系疾病临床应用的专家共识》、2024年《消化不良中国家庭合理用药专家建议（科普实践版）》及《功能性便秘中西医结合诊疗专家共识（2025年）》等全国共识意见。